Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: A post hoc analysis of the GOAL study

Jean Bousquet, Neil Barnes, Michael Gibbs, Nadeem Gul, Susan A. Tomkins, Xin Zhou, Young Joo Cho, Hae Sim Park, William Busse, Nanshan Zhong

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods: A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results: In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions: A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups.

Original languageEnglish
Article number75
JournalBMC Pulmonary Medicine
Issue number1
StatePublished - 28 Apr 2017

Bibliographical note

Funding Information:
This study was funded by GSK (SAM40027). Employees of GSK were involved with the study design, data analysis and writing of the manuscript.

Funding Information:
Editorial support (in the form of writing assistance, including development of the initial draft based on author input, assembling tables and figures, collating authors comments, grammatical editing and referencing) was provided by Gillian Groeger, PhD, of Fishawack Indicia Ltd, UK, and was funded by GlaxoSmithKline (GSK).

Publisher Copyright:
© 2017 The Author(s).


  • Asian patients
  • Asthma
  • Asthma control
  • Asthma treatment
  • Fluticasone propionate/salmeterol
  • ICS/LABA treatment


Dive into the research topics of 'Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: A post hoc analysis of the GOAL study'. Together they form a unique fingerprint.

Cite this